Medical imaging software developer ISG Technologies has named Max Rutherford president and COO of the Mississauga, Ontario, company. Rutherford fills a position once held by Thomas Cafarella, the former ISG executive who participated in a takeover bid
Medical imaging software developer ISG Technologies has named Max Rutherford president and COO of the Mississauga, Ontario, company. Rutherford fills a position once held by Thomas Cafarella, the former ISG executive who participated in a takeover bid for ISG after he was released from the company last year (SCAN 1/8/97).
Rutherford comes to ISG from CAE Electronics, a flight-simulator company, where his last two posts were vice president of business development and vice president of engineering. ISG got its start as a flight-simulator developer before shifting to medical imaging.
Rutherford will be responsible for ISG's business units and operations groups. He will report to Dr. Michael Greenberg, who remains ISG's chairman and CEO.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 2nd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 2nd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 2nd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.